AmoyDx
Manufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Xiamen, Fujian, ChinaPhone Number
+86 5926806835Website
www.amoydiagnostics.comRevenue
$139.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About AmoyDx
AmoyDx is a visionary diagnostic company focused on transforming cancer care through innovative diagnostic tools. They offer a range of products including the HANDLE OncoPro Panels, HANDLE Hereditary Cancer NGS Panel, and HANDLE Insight NGS Panel, aimed at enhancing precision oncology. Their services cater to oncologists and the pharmaceutical industry, providing decentralized and user-friendly companion diagnostic solutions. Committed to values such as innovation, accessibility, collaboration, and integrity, AmoyDx strives to make precision cancer care accessible to every patient.Explore more
AmoyDx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AmoyDx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if AmoyDx has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on AmoyDx recently announced quarterly report
Click to see if AmoyDx had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at AmoyDx
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when AmoyDx launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if AmoyDx is spiking on competitors!
Funding: Get notified immidiatlly once AmoyDx has new funding data
AmoyDx, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
AmoyDx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AmoyDx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AmoyDx.
AmoyDx Tech Stack
A closer look at the technologies used by AmoyDx
Most Recent Scoops
Event
Product Marketing, Events, Training, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Technology
Event
Product Marketing, Events, Software, Field /Outside Sales, Field Marketing, Healthcare Operations, Healthcare Technology
Event
Events
Event
AmoyDx News & Media
AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan
SHANGHAI, China, April 18, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a Master Collaboration Agreement (Agreement) with AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company. The master collaboration agreement enables the Parties to collaborate in the development and commercialization of AmoyDx assays that may cover any type of indicationNotice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
TOKYO and XIAMEN, China, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent for multiple antineoplastic agents, was submitted in February 2022 (hereinafter referred to as the "Application for Partial Change").AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, China, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for TEPMETKO® (tepotinib) a Merck KGaA, Darmstadt, Germany product that received approval by the Japanese MHLW in March 2020. TEPMETKO (tepotinib)AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
TOKYO and XIAMEN, China, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent developed as a companion diagnostic for multiple anti-cancer agents, was approved by Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on June 25, 2021. The
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AmoyDx
Sign Up For FreeTo access detailed company insights
AmoyDx is a visionary diagnostic company focused on transforming cancer care through innovative diagnostic tools. They offer a range of products including the HANDLE OncoPro Panels, HANDLE Hereditary Cancer NGS Panel, and HANDLE Insight NGS Panel, aimed at enhancing precision oncology. Their services cater to oncologists and the pharmaceutical indu... Read More
